期刊
CANCER JOURNAL
卷 18, 期 5, 页码 404-410出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/PPO.0b013e31826c5810
关键词
B-cell receptor; PI3K; Bruton's tyrosine kinase; Syk; PCI-32765; GS-1101; AVL-292
类别
资金
- National Institutes of Health [5R37CA049870]
- Tower Cancer Research Foundation
The B-cell receptor (BCR) complex and its associated protein tyrosine kinases play a critical role in the development, proliferation, and survival of normal or malignant B cells. Regulated activity of the BCR complex promotes the expansion of selected B cells and the deletion of unwanted or self-reactive ones. Compounds that inhibit various components of this pathway, including spleen tyrosine kinase, Bruton's tyrosine kinase, and phosphoinositol-3 kinase, have been developed. We summarize the rationale for use of agents that can inhibit BCR signaling to treat patients with either indolent or aggressive B-cell lymphomas, highlight early clinical results, and speculate on the future application of such agents in the treatment of patients with various B-cell lymphomas.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据